Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive drug tested to target advanced prostate cancer

NCT ID NCT06531499

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a radioactive drug called AAA617 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to see where the radiation goes in the body, measure how much radiation organs and tumors receive, and check the drug's safety and side effects. About 106 participants who have not had chemotherapy will receive up to 12 doses of the drug, given every 6 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Mayo Clinic Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Novartis Investigative Site

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    RECRUITING

    Wuppertal, North Rhine-Westphalia, 42283, Germany

  • Novartis Investigative Site

    RECRUITING

    Aachen, 52074, Germany

  • Novartis Investigative Site

    RECRUITING

    Berlin, 13353, Germany

  • Novartis Investigative Site

    RECRUITING

    Essen, 45147, Germany

  • Novartis Investigative Site

    RECRUITING

    München, 80377, Germany

  • Novartis Investigative Site

    RECRUITING

    Rostock, 18057, Germany

  • Novartis Investigative Site

    RECRUITING

    Nijmegen, Gelderland, 6500HB, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    RECRUITING

    Majadahonda, Madrid, 28222, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    RECRUITING

    Bellinzona, 6500, Switzerland

  • Novartis Investigative Site

    RECRUITING

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Glasgow, G12 0YN, United Kingdom

  • Stanford University

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact

    Contact Email: •••••@•••••

  • University of California LA

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Email: •••••@•••••

  • Wash U School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER